Patent cliffs, partners and petrol

Mayr-Melnhof, Ubisoft, BASF, Sanofi, Solaria, Commerzbank, IGD, PORR, Flughafen Wien, Ferrari Group, Interparfums, Sage, Rubis, Novartis

Patent cliffs, partners and petrol

At Lux Opes, we break down companies into quick takes that get straight to the point - what is happening, why it matters, and what to watch next.

For the best reading experience, we recommend reading at Lux Opes

Financial KPIs

CompanyPriceMkt capEV/ EBITDA*P/E*Cons. upside
Sage1124.5010,18415.7x22.4x7.8%
Ubisoft4.265922.9x–16.3%
Solaria14.971,9868.8x10.4x47.2%
Rational610.006,93616.5x25.3x30.8%
Flughafen Wien50.004,20010.1x21.8x12.7%
PORR32.301,2691.8x9.8x30.3%
Eurocash56543.7x–13.5%
Ferrari Group8.107406.9x13.6x35.6%
Novartis127.90260,25314.9x16.7x1.8%
Rubis36.623,7877.0x10.7x14.4%
Interparfums36.143,18017.7x26.8x-1.6%
IGD549713.2x11.9x10.2%
Commerzbank38.0841,159–12.3x12.9%

* Next fiscal year (FY+1). Cons. upside = gap to the average 12-month analyst price target (Bloomberg consensus), not a Lux Opes view. Local currency (Sage: share price data in pence, other figures in £m; Novartis: price, market cap, debt, cash and EV in CHF, sales, EBITDA and EPS in USD, its reporting currency); market cap in millions. Source: Bloomberg, analyst consensus.

All financial KPIs13 companies · 50 data rows from BloombergShow
Local currencySageUbisoftSolariaRationalFlughafen WienPORREurocashFerrari GroupNovartisRubisInterparfumsIGDCommerzbank
Price and shares
Latest fiscal year2025 A2026 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A2025 A
Latest period end31/0331/0330/0630/0930/0631/1230/0630/0630/0930/0630/0630/0930/09
52-week high1208.008.0925.85776.5056.0046.55811.26137.0037.2037.20543.37
52-week low771.803.7013.61553.5048.1026.3547.0999.4530.3020.74329.32
Vs 52-week high-6.9%-47.4%-42.1%-21.4%-10.7%-30.6%-40.4%-28.1%-5.5%-1.6%-2.8%-5.2%-12.2%
Vs 52-week low45.7%15.0%10.0%10.2%4.0%22.6%14.4%14.2%30.2%20.9%74.2%37.6%29.9%
Volume, previous day3,022,801467,485792,8468,91651366,437350,35781,689204,2797,3139,177215,442799,739
Current price1124.504.2614.97610.0050.0032.3058.10127.9036.6236.14538.08
Shares outstanding (m)987.9132.2132.611.483.939.3139.291.32,034.8103.487.8110.31,073.8
Market value
Market cap (m)10,1845921,9866,9364,2001,269654740260,2533,7873,18049741,159
Total debt2,0221,7941,53938576902,2945240,3442,420128796181,252
Preferred stock––––––––––––3,884
Minority interest–(74)5–1623281152811211–1,710
Cash & equivalents5181,346219512981,2183691317,4957321152285,071
Enterprise value (m)11,6889663,3116,4624,3217732,661676293,3835,6893,1941,271–
Analysts
Buy ratings1421214192594837
Hold ratings47723–2–1623210
Sell ratings2421––3–411–2
Target price (12m)1,211.854.9522.04797.6056.3742.095.3310.98130.2441.8935.554.9642.97
Return potential7.8%16.3%47.2%30.8%12.7%30.3%13.5%35.6%1.8%14.4%-1.6%10.2%12.9%
Estimates
LFYSales (m)2,5131,3961971,2601,1296,29630,02435956,6746,53489912924,344
FY+12,7661,3953831,3321,0946,51228,25237756,8457,68187313313,115
FY+23,0201,6344791,4331,1366,75628,77240160,6707,77696013214,151
LFYEV/Sales4.7x0.7x16.8x5.1x3.8x0.1x0.1x1.9x6.2x0.9x3.6x9.8x–
FY+14.2x0.7x8.7x4.9x3.9x0.1x0.1x1.8x6.2x0.7x3.7x9.6x–
FY+23.9x0.6x6.9x4.5x3.8x0.1x0.1x1.7x5.8x0.7x3.3x9.7x–
LFYEBITDA (m)6483802663714703015437623,96777920698–
FY+17443343753914284387139823,57781118196–
FY+283361645141545046288710525,91583819495–
LFYEV/EBITDA18.0x2.5x12.5x17.4x9.2x2.6x4.9x8.9x14.7x7.3x15.5x13.0x–
FY+115.7x2.9x8.8x16.5x10.1x1.8x3.7x6.9x14.9x7.0x17.7x13.2x–
FY+214.0x1.6x7.3x15.6x9.6x1.7x3.0x6.4x13.6x6.8x16.5x13.3x–
LFYEPS0.40(10.51)1.1022.332.732.46(2.28)0.467.752.981.500.312.47
FY+10.50(1.55)1.4424.122.303.30(1.35)0.609.073.431.350.383.08
FY+20.58(0.21)1.6425.502.303.640.460.6410.023.491.450.423.78
LFYP/E28.6x–13.6x27.3x18.3x13.1x–17.6x19.8x12.3x24.0x14.6x15.4x
FY+122.4x–10.4x25.3x21.8x9.8x–13.6x16.7x10.7x26.8x11.9x12.3x
FY+219.5x–9.1x23.9x21.8x8.9x10.3x12.7x15.1x10.5x24.9x10.8x10.1x
Growth and margins
1 YearRevenue growth7.8%-21.8%11.6%5.5%7.2%1.7%-4.6%3.0%9.6%-1.6%2.1%-4.1%-1.9%
5 Year5.8%-7.3%33.3%14.6%29.4%6.3%3.7%11.6%3.1%12.9%20.8%-2.3%21.4%
1 YearEBITDA growth22.7%-33.0%31.9%2.8%5.2%-4.1%-39.8%-15.7%7.0%3.3%2.7%-4.5%–
5 Year5.8%-13.9%43.5%20.1%64.7%55.3%-4.1%5.9%6.9%5.1%34.6%-1.3%–
LTMEBITDA margin26.0%27.2%–30.2%37.8%4.8%1.8%24.7%40.1%11.5%21.7%64.6%–
FY+126.9%23.9%–29.4%39.1%6.7%2.5%25.9%41.5%10.6%20.7%72.4%–
FY+227.6%37.7%–28.9%39.6%6.8%3.1%26.2%42.7%10.8%20.2%72.6%–
Balance sheet
Total debt / equity919%122%142%4%4%74%796%25%130%86%18%78%598%
Total debt / capital90%56%59%4%3%42%86%19%56%45%15%44%83%
Total debt / EBITDA3.0x4.7x4.6x0.1x0.1x2.3x4.5x0.6x2.1x2.9x0.7x9.7x–
Net debt / EBITDA2.2x1.2x3.9x-1.2x-0.1x-1.8x3.7x-0.9x1.7x2.1x0.1x9.4x–
EBITDA / interest10.2x4.3x6.1x198.9x101.1x8.0x1.8x25.7x15.3x8.9x38.3x1.6x–

Local currency (Sage: share price data in pence, other figures in £m; Novartis: price, market cap, debt, cash and EV in CHF, sales, EBITDA and EPS in USD, its reporting currency); market cap in millions. Source: Bloomberg, analyst consensus. On a phone, swipe the table sideways to see every company.


Mayr-Melnhof (MMK Austria): The new range leaves the mills it keeps near break-even at best

● NEGATIVE

Mayr-Melnhof expects to write down €250-300m of assets in its Board & Paper division for 2026, mainly because it now expects weaker cash flows there, and a net loss of €270-340m. It put adjusted EBITDA for 2026 at €300-320m, held back by a sharp rise in energy costs at the mills. After €259.1m in nine months, the range leaves €41-61m for the fourth quarter, less than packaging alone has earned in an average quarter this year.

Mayr-Melnhof's new profit range for 2026 tells us that the board mills it has chosen to keep will earn little or nothing in the last quarter of the year. They will probably lose money, even after the price rises the company began in October. Mayr-Melnhof (MM), based in Vienna, makes cartonboard, the stiff board used for food and medicine boxes, in mills across Europe, and it also turns board into folding cartons. On 9 November it agreed a deal in which the private equity firm KPS Capital Partners (KPS) takes 70% of the carton business, its packaging arm. Once the deal closes, MM will be mainly a board and paper maker.

The release of 19 November brought two pieces of bad news for that remaining business. The first is a non-cash write-down of €250-300m on the Board & Paper division, covering both plants and goodwill, the premium paid for past acquisitions. The company puts it down mainly to "weaker cash flow projections". The second is a range for adjusted EBITDA, operating profit before depreciation and one-off items, of €300-320m for 2026. MM blames the level on the sharp rise in energy costs at the mills. MM had given no number for this year's profit until now.

The mills already slipped to a loss in the third quarter, with adjusted EBITDA of minus €18.1m. The loss came after about €36m of costs for planned maintenance shutdowns at two mills, so without them the division earned roughly €18m. In March MM put this year's shutdown costs at around €40m, which would leave only a few million for the fourth quarter. A normal quarter, with October's higher prices, should therefore have brought the mills back into profit.

Instead, the range leaves almost nothing for the mills in the fourth quarter, because packaging alone usually earns more than the whole group has left. After €259.1m of adjusted EBITDA in nine months, the group has only €41-61m left for the last three months of the year. The two packaging divisions earned €76.9m in the third quarter and €72.6m in the last quarter of 2025. If packaging earns even €60m in the fourth quarter, the mills would make close to nothing before depreciation. On a more normal packaging quarter, they lose money for a second quarter running, this time without large shutdown costs to explain it.

The mills that shareholders will keep once KPS takes control of packaging have a weak record, and the company has now written them down for the second year running. In our note of 10 November we called the price for packaging good but worried that the deal left MM with a volatile board business. The mills had barely made an operating profit, €3.4m before one-off items in 2025 after a loss in 2024, in a European market with too much capacity. In February MM had flagged €65-75m on Board & Paper in its 2025 accounts, and it booked €70.5m, also citing weaker long-term cash flow projections.

The other reading is that this is a temporary energy shock that higher prices will soon cover. MM linked the higher energy, chemicals and transport costs to the conflict in the Middle East, and it says it has been raising prices since October. Its board order backlog was also higher than a year earlier, and its cost savings keep coming through. The price KPS is paying could also point to a weak last quarter in packaging, which would leave more for the mills. That price, about nine times what packaging is expected to earn this year before depreciation and one-off items, suggests roughly €46m for the quarter. But that multiple leaves out the plants in Iran and Tunisia, so packaging as a whole should earn more than €46m. What tips the balance for us is MM's own nine-month statement, which said overcapacity in the market "continues to constrain the full pass-through of sharply rising energy costs". A guidance range that points to losses at the mills, weeks after the price rises began, suggests the market is still setting the price, not MM. For MM shareholders the release is negative, because it weakens the business they will keep once the KPS deal closes.

Sources we read for this take

Company: Mayr-Melnhof release on 2026 impairment and guidance (19 Nov 2026); MM trading statement for the first three quarters of 2026 (5 Nov 2026); MM release on the KPS deal for its packaging business (9 Nov 2026); MM release on 2025 impairment (5 Feb 2026); MM annual results 2025 (17 Mar 2026); MM half-year 2026 results (20 Aug 2026); MM financial calendar (read 19 Nov 2026)

History: our take of 10 Nov 2026 on the KPS deal

Our earlier take: Record coverage (10 Nov 2026)


Ubisoft (UBI France): A hit remake lifted the quarter, but the year hangs on when partner deals land

● NEUTRAL

Net bookings fell 16.5% to €644.7m in the six months to September, but the second quarter beat guidance. Ubisoft kept its targets for the year, which with about €250m guided for the third quarter leave roughly €490m to €525m for January to March, against €415m a year earlier. Cash was €1.03bn before a €453m bond repayment in November.

Market cap €592m  ·  EV €966m  ·  EV/EBITDA forward 1.9x  ·  Consensus upside 16.3%

Ubisoft's second quarter was better than it promised and healthier than a year ago, but the target for the year now depends on partner deals arriving before March, and their timing has slipped before. The French company makes video games such as Assassin's Creed, Far Cry and Rainbow Six Siege. Its main series sit in Vantage Studios, a subsidiary in which Tencent, the Chinese games group, paid €1.16bn for a minority stake.

Ubisoft has spent the past two years in a long reset, and net bookings, the sales measure it prefers, fell 17% to €1.53bn in the year to March 2026, after games were cancelled or delayed. Ubisoft guided to another fall this year, before bigger launches from 2027-28. In the second quarter a remake of an old Assassin's Creed game, Black Flag Resynced, sold better than expected, and net bookings came in about €19m above guidance.

Outside partner deals, bookings grew in the first half, which matters more than the size of the beat. Partner deals are licensing and distribution agreements with other companies, such as platforms that pay to carry Ubisoft games. A year ago first-half net bookings rose 20%, which our take of November 2025 said was "helped by better-than-expected partner deals", adding that Ubisoft used such deals "to fill financial gaps". Now Ubisoft says second-quarter net bookings excluding partnerships rose more than 50% from a year earlier, even though total bookings for the quarter fell 21% against last year's deal-heavy quarter. Rainbow Six Siege has also recovered after changes to its ranked mode, and its October bookings doubled.

Ubisoft expects only about €250m of net bookings for October to December, a quarter less than a year earlier. It says the figure reflects, as it expected, a "particularly crowded holiday season". The release names no rival, but one likely reason is the new Grand Theft Auto game from Rockstar, which goes on sale on 19 November, the day of Ubisoft's results. Fox10 reported on 15 October that Rockstar had confirmed that date.

Keeping the target therefore needs a January to March quarter of roughly €490m to €525m. Ubisoft expects a high single-digit fall in net bookings for the year to March 2027, so somewhere around €1.39bn to €1.42bn. The first half and third quarter add up to about €895m. Last year's final quarter brought €415m, but that was a quiet quarter with no big launch and far less partner income than the record quarter a year earlier, when Assassin's Creed Shadows came out. Two games came out in the third quarter, Rayman Legends Retold and Just Dance: Decades of Hits. Beyond those, Ubisoft points for the second half to continued Black Flag sales, a strong final quarter for Siege, new premium games still "to be announced", and a "material contribution from partnerships".

The first half made an operating loss of €156m on Ubisoft's adjusted measure. A loss margin in the high single digits for the year means the second half must earn an adjusted operating profit of roughly €30m to €57m. With October to December guided low, most of that profit also has to come in the final quarter.

Net debt rose to €541m in September from €187m in March, so the cash cushion has thinned. Holders of convertible bonds due in 2028 asked for €453m back early, and Ubisoft paid this in November from cash. That leaves cash of under €580m, before any spending in October and November. First-half free cash flow was an outflow of at least €324m, and the target caps it at €500m for the year, so the second half can use at most about €175m. In May we noted that cash covered the November repayment and that options were being studied for later debts. Ubisoft now says the second part of its refinancing "will launch shortly".

Partner deals can easily close the gap of roughly €75m to €110m over last year's final quarter. Ubisoft's own figures suggest such deals brought at least about €185m in last year's first half. Bookings outside them grew by double digits this half, while the total fell 17%. Ubisoft has also beaten its quarterly guidance three times in a row and kept the target after seeing October trading. What tips the balance towards a shortfall is timing. Postponed partnerships were one cause of Ubisoft's profit warning of January 2026, and the premium games meant to help have not yet been named. The business is improving, but the target rests on deals and games still unknown, so our sentiment is neutral.

Sources we read for this take

Company: H1 2026-27 earnings release (19 Nov 2026); Q1 2026-27 sales release (Jul 2026); FY 2025-26 earnings release (20 May 2026)

Reported: Fox10 on Rockstar's confirmed 19 Nov 2026 release date for the new Grand Theft Auto game (15 Oct 2026)

Track record: first-half net bookings growth helped by partner deals, from our take of 25 Nov 2025; cash and maturities, and the January 2026 profit warning citing postponed partnerships, from our take of 21 May 2026

Our earlier take: Weapons, AI Infra and some losers (21 May 2026)


BASF (BAS Germany): Dropping Evonik keeps the payout promise safe, but extra payouts look unlikely

● NEUTRAL

BASF ended its pursuit of Evonik on 19 November, citing a board that would not engage and a standalone outlook that did not support a higher valuation. It received about €5.8bn before tax for its coatings business in June, and about €1.5bn of the buybacks it has promised for 2025 to 2028 remain after the current one. In July BASF kept its new buyback inside the existing plan and said it would significantly reduce net debt.

BASF's decision on 19 November to stop pursuing Evonik keeps its payout promise safe, but an extra payout is unlikely when it sets out its plans to investors next week. BASF, the German chemicals group with around €60bn of sales in 2025, makes basic chemicals, plastics, ingredients for food and care products, and crop protection for farmers. Evonik is a smaller German rival that makes amino acids for animal feed, high-performance polymers and ingredients for beauty products. BASF has promised at least €12bn of dividends and share buybacks from 2025 to 2028. A takeover of Evonik would have cost more than the €5.8bn before tax that BASF received in June for its coatings business, putting that promise under strain.

BASF had tried since September to take over Evonik, but got nowhere with its board. Evonik's board turned down two cash proposals, the second at €24 a share. Reuters reported that offer was worth more than €11bn for Evonik's shares. As recently as 17 November, Bloomberg and Reuters reported, citing people familiar with the matter, that BASF was preparing a new offer with pledges on plants and jobs. BASF did not confirm the reports. It now says Evonik's board "has not shown meaningful engagement until today", although BASF had been ready to consider "a further moderate increase". Its assessment of Evonik's standalone prospects, and of the risks, "did not provide sufficient grounds to justify a higher valuation". Our own doubt, in our note of 10 November, was that part of Evonik's strong third quarter rested on a supply disruption that will not last forever. Our test of 18 November, that BASF would not file an offer naming savings to cover a higher price by 31 December, has held so far.

With the deal gone, the buyback part of the promise is within reach, since the coatings money no longer has to fund a takeover. BASF has pledged buybacks of at least around €4bn, alongside a yearly dividend of around €2bn. About €2.5bn of the buybacks is done or running, including up to €1bn set in July that runs to the end of April 2027. If that is used in full, about €1.5bn is left for the following 20 months, or roughly €0.9bn a year. That is a modest sum next to the €5.8bn before tax that coatings brought in this year, even after the debt repayment set out below.

The other reading is that with Evonik off the table, BASF will return more of the coatings money to shareholders, perhaps money it held back in July with a bid in mind. The release says ending the pursuit underlines its commitment to "disciplined capital allocation and attractive shareholder distributions". BASF has also shown it will use disposal money this way, having brought its first buyback forward in October 2025 because of cash from its portfolio measures. Trading has helped too, with BASF raising its 2026 profit outlook in July and again in October.

What decides it for us is that the better trading has not changed BASF's cash outlook. It kept its guidance for free cash flow, the cash left after investment, at €1.5bn to €2.3bn this year, about what the yearly dividend costs. Any extra payout would therefore have to come from disposal money. In February its finance chief said a substantial part of this year's disposal cash would go to strengthening the balance sheet. In July, with the coatings money in hand, BASF acted on that by keeping the new buyback inside its existing plan and repaying €1.6bn of bonds and loans early. BASF links lower debt to keeping its current single-A credit rating, a high grade that keeps its borrowing cheap. For BASF's shareholders the balance is neutral: the risk of an expensive deal has gone, but BASF's own plans point to sticking with the minimum.

Sources we read for this take

Company: BASF release P-26-202 (19 Nov 2026); BASF buyback and debt release P-26-142 (29 Jul 2026); BASF coatings closing release P-26-113 (1 Jul 2026); BASF half-year 2026 release P-26-123 (29 Jul 2026); BASF Q3 2026 release P-26-180 (28 Oct 2026); BASF full-year 2025 release P-26-020 (27 Feb 2026); BASF capital markets day page (read 19 Nov 2026)

Reported: Reuters (17 Nov 2026), citing people familiar with the matter, including Bloomberg's report of the same day; not confirmed by BASF

History: Evonik Q3 2026 results, from our take of 10 Nov 2026

Prior test: held: BASF said on 19 Nov 2026 it will end its efforts to acquire Evonik; no offer filed as of 19 Nov 2026, scored now unless BASF returns before 31 Dec 2026

Our earlier take: Short sellers, frigates and perfume (18 Nov 2026)


Sanofi (SAN France): Insmed would cost earnings first, because the premium pays for sales still years away

● NEUTRAL

Bloomberg reports, citing people familiar with the matter, that Sanofi is weighing a takeover of Insmed, an American maker of lung medicines valued at about $26.6bn. Both companies declined to comment, so nothing is confirmed. On our estimate, borrowing Insmed's market value and taking on its loss would cut Sanofi's business net income by close to 8% at today's figures. A 50% premium would add about 2.6 points more.

Buying Insmed would give Sanofi the lung drugs it needs after Dupixent, but it would cost earnings first, because a takeover premium would pay for sales that are still years away. Sanofi is the French drugmaker behind Dupixent, an injection for eczema, asthma and other allergic diseases. Dupixent brought in €5.7bn in the third quarter, close to 40% of group sales. On 19 November Bloomberg reported, citing people familiar with the matter, that Sanofi is weighing a takeover of Insmed, an American company that makes medicines for lung diseases. Both companies declined to comment, so the report is not confirmed.

Dupixent's main US patent runs out in March 2031, though Sanofi plans to defend later patents, and its chief executive, Belén Garijo, has made life after it the group's main task. On 30 October she said the whole group is focused on "managing Sanofi's post-Dupixent trajectory over the next decade". She added that buying and licensing in new drugs "will be critical to complement this transformation". In December 2025, when tolebrutinib, Sanofi's most advanced drug for multiple sclerosis, failed one trial and saw its US approval decision delayed, we wrote that Sanofi leaned more on one drug than before. Dupixent was then about a third of sales, and its share has since risen to close to 40%. This year Sanofi paid €1.6bn for Dynavax, which added a vaccine to its range. Insmed would be a far bigger step, worth about a quarter of Sanofi's own value before any premium, on the figures in the Bloomberg report.

Insmed's main drug is Brinsupri, a tablet for bronchiectasis, a disease in which damaged airways fill with mucus and get infected again and again. It went on sale in the US in the third quarter of 2025, and a year later it sold $400m in a quarter, up 29% from the quarter before. Insmed also sells Arikayce, an inhaled antibiotic for a rare lung infection. Its other big hope is TPIP, an inhaled powder for high blood pressure in the lungs and for lung scarring. TPIP is in three late-stage studies, and a fourth is due to start in the first half of 2027.

The two companies fit well, because both deal with the same lung doctors. Dupixent is already approved for asthma and for chronic obstructive pulmonary disease (COPD), a long-term lung disease. With Brinsupri added, Sanofi's sales teams would have more to offer these doctors once Dupixent faces cheaper copies.

Most of what Insmed promises lies years ahead, in its own peak sales forecasts of more than $7bn a year for Brinsupri, more than $6bn for TPIP and more than $1bn for Arikayce. Together that is about €12.7bn, a little over half of what Dupixent sells today at its third-quarter pace, and Dupixent is still growing. More than 40% of that total is TPIP, which has finished none of its late-stage studies and could still fail. Enrolment in the most advanced of them, for high blood pressure linked to lung scarring, is only due to finish in the first half of 2028.

The cost of a deal would come much sooner, mostly as interest. Sanofi held €6.0bn of cash at the end of September, about a quarter of Insmed's market value, so most of a deal would need new debt. In the third quarter Sanofi's net financial costs ran at about 3.3% a year of its net debt. That is a low estimate for new borrowing, because it is reduced by interest earned on cash. At that rate, borrowing Insmed's market value alone would cost about €0.6bn a year after tax, at the roughly 21% tax rate Sanofi expects for 2026. That is about 5% of Sanofi's business net income, its adjusted profit, which ran at about €12bn a year over the first nine months. Insmed's loss at its third-quarter pace, after tax inside Sanofi, would add about €0.3bn, for a drag of close to 8% at today's figures. Garijo says her priority is "to protect earnings through Dupixent's loss of exclusivity".

The other reading is that Insmed could pay its own way by the first full year after a deal, which would most likely be 2028. Last year's third-quarter loss included a non-cash charge of about $105m for revaluing payments Insmed still owes on an earlier purchase, against $8m this year. Without that charge, the loss shrank by about $0.7bn a year at the quarterly pace. Its chief executive says the US launch of Brinsupri "continues to exceed expectations". If that trend continues, Insmed's own profit, plus savings on overlapping sales and overhead costs, could cover the interest on its market value. What tips the balance our way is the premium on top. A 50% premium, for example, would add about €0.3bn a year of interest after tax, or about 2.6% of business net income. The 3.3% rate used here is also low for new borrowing, and savings usually take more than a year to arrive. And Insmed's trend depends on Brinsupri's growth continuing while spending on three late-stage TPIP studies rises. A rival bidder, which Bloomberg says could emerge, would push the premium higher.

Sources we read for this take

Reported: Bloomberg (19 Nov 2026), via Reuters and Investing.com (19 Nov 2026), with both companies declining to comment; Fierce Pharma (read 19 Nov 2026) on Dupixent's March 2031 US patent

Company: Sanofi Q3 2026 results release (30 Oct 2026)

Target: Insmed Q3 2026 results release (29 Oct 2026)

History: Dupixent's share of sales and the tolebrutinib setbacks, from our take of 16 Dec 2025

Our earlier take: Wine, packaging and lots of divestments (16 Dec 2025)


Solaria (SLR Spain): The 2029 goal mostly adds a year to the old plan, and leans on batteries

● NEUTRAL

The EBITDA goal for 2028 stays at €521m, and 2029 is set at €540-560m. About €140m a year of battery cash for Solaria is to come from 5 GWh of batteries, while the only working example shown holds 50 MWh.

Market cap €2.0bn  ·  EV €3.3bn  ·  EV/EBITDA forward 7.4x  ·  Consensus upside 47.2%

Solaria's higher profit goal mostly adds one year to the plan it presented a year ago. With far fewer new parks to come, it now leans on batteries and on more land deals for data centres. The Spanish company builds and runs solar parks, mainly in Spain, and sells the power they produce. It also sells land with a grid connection to companies that build data centres. At its investor day in London today, it set a target of €540m to €560m of EBITDA, its operating profit before depreciation, for 2029, against €266m in 2025.

Forbes España reported a year ago, after last year's investor day, that Solaria planned to keep building fast, to 9 gigawatts (GW) of plants in operation by 2028, with EBITDA of €521m that year. Today it expects about 3.5 GW at the end of this year and sets no goal for new solar or wind capacity after that. It plans to invest roughly half as much over 2027 to 2029 as it then planned for 2026 to 2028. Its profit goal for 2028, however, is still €521m in today's presentation, so the new goal for 2029 adds only 3.6% to 7.5% on top.

Land sales have carried much of this year's growth, a pattern our take of 2 October 2025 had already noted. Infrastructure sales, mostly payments from data-centre developers for land with a grid connection, made €115m of the €260m of sales over nine months. Only about €15m of that came in the third quarter, which shows how uneven these payments are. In Spain, Solaria now wants to own part of the data centres instead, starting with a joint venture in Madrid, owned half and half with a European partner. The venture should earn about €70m of rent a year before costs once the centre is full, half of it due to Solaria, but it is being built until 2030.

Much of the extra profit, as we read the plan, has to come from about 5 gigawatt hours (GWh) of batteries at Solaria's solar parks in Spain. They cost €440m, and once all of them run at the end of 2028, Solaria expects about €140m of cash a year for itself, after its partner's share. It gives no profit figure for them. About a quarter should run by the end of this year and 4.1 GWh by the end of 2027. The idea makes sense to us, because Spanish solar parks all produce at the same hours, so prices fall when the sun is strongest. Solaria sold its Spanish power for an average of only €44 per megawatt hour (MWh) over nine months. A battery stores power when it is cheap and sells it when it is dear.

The batteries matter most in 2027, when EBITDA is planned to rise by about €125m, or 38%, to €456m. The presentation does not split that step. Before EBITDA can grow, Solaria has to repeat this year's land income. After that it rests on the first full year of the parks added in 2026 and on batteries coming into service during 2027. New data-centre deals can help too, and for its other data-centre sites Solaria still lists an outright sale among the options. Our rough estimate puts the batteries at the centre of it. About 1.2 GWh should run at the start of 2027, 2.9 GWh by mid-year and 4.1 GWh at the end. At the platform's average of about €28m of cash per GWh, that is close to €80m for Solaria in 2027. The rise over 2026 is smaller, because part of the 1.2 GWh already earns this year, and cash is not EBITDA. Even so, batteries could supply roughly half of the €125m step, more than any other source the plan puts a figure on.

The weak point is that the only figures Solaria shows for the €140m come from one small plant. Solaria's battery in Castile and León, 50 MWh or about 1% of the planned platform, sold power from January to October for an average of €115.6 per MWh more than it paid to store it. Price gaps that wide tend to attract more batteries, which then narrow them. Grenergy, a Spanish rival, has signed long-term financial tolling agreements with utilities for two Spanish batteries of about 1.3 GWh, starting in 2028. Such contracts swap part of the trading income for agreed payments. Solaria's presentation mentions no tolling contracts for its batteries.

The other reading is that Solaria has met its recent profit targets, so its battery forecast deserves some trust. EBITDA of €266m in 2025 was 6.4% above the goal, and this year's €331m needs only about €32m in the fourth quarter, against about €35m a year ago. What tips the balance towards caution is its record on building, because the 2027 goal needs the battery fleet to more than triple within the year. In December 2024 Solaria expected to go from 1.7 GW to 3.1 GW during 2025, and at its half-year results it still expected about 3 GW, as our take of 2 October 2025 reported. It ended the year with 2.35 GW.

Solaria's debt has fallen relative to its profit this year, to 4.2 times EBITDA in September from 5.4 times at the end of 2025, inside the 4.8 times it had set for 2028. Of the €440m for batteries, €370m is already funded by April's share sale and money from a partner. For 2027 to 2029 Solaria counts on €1.1bn of operating cash flow, enough for the equity its growth needs and for raising its holding of its own shares to 10% of the capital. More than €0.6bn of that comes from plants already running, which alone covers the €512m of equity the growth needs. If price gaps narrow, it is mainly the share purchases that would have to wait.

Sources we read for this take

Company: Capital Markets Day release and presentation (19 Nov 2026); 9M 2026 results release (19 Nov 2026); H1 2026 results release (24 Sep 2026); capacity plan release (5 Dec 2024)

Reported: Forbes España (17 Nov 2025)

Peers cross-read: Grenergy tolling agreements for Oviedo (17 Feb 2026) and Escuderos (27 Apr 2026)

Track record: capacity plan for 2025 against delivery, from our take of 2 Oct 2025

Our earlier take: DIY, luxury fashion and Russian controversies (2 Oct 2025)


Commerzbank (CBK Germany): Berlin's deal leaves the bank's other holders without an ally on price

● NEUTRAL

Reuters and dpa report that the German state now backs an orderly handover of control to UniCredit, which has access to just under 50% of Commerzbank's voting rights. We found no release from either bank with the terms of Orcel's letter, so they are reported, not confirmed. If the state's 13.3% votes with UniCredit, opponents of a domination agreement, the step that lets a parent give binding orders, would need more than a fifth of all shares.

Market cap €41.2bn  ·  P/E forward 10.3x  ·  Consensus upside 12.9%

Berlin has won promises that keep Commerzbank listed and run from Frankfurt, but none of them protects the price its other shareholders will get. Commerzbank is Germany's second-largest private bank, with more than 11 million private and business customers at home. UniCredit, the Italian bank that already owns HypoVereinsbank (HVB) in Munich, has spent two years building its stake and has access to just under half of the voting rights. The European Commission cleared the takeover on 16 November. The terms below come from a letter by UniCredit's chief executive, Andrea Orcel, and from the finance minister's statement, as reported by Reuters and dpa.

The German state has owned part of Commerzbank since it rescued the bank in 2009, and holds 13.3% today. Its finance ministry called UniCredit's bid "aggressive and hostile" as recently as September, EUobserver reports. On 19 November finance minister Lars Klingbeil said the government "supports a swift process and an orderly transition of control". He spoke after Orcel's letter of 18 November, in which Orcel wrote that he was "prepared to commit" to a series of "binding principles". Commerzbank said it welcomed UniCredit's commitments.

According to Klingbeil, Commerzbank is to stay a listed company based in Frankfurt. It is to grow its business with mid-sized firms, keep adequate capital and take key decisions in Germany. Orcel's letter adds that after a merger with HVB, Frankfurt is to become the head office, with a large presence kept in Munich. The state drops its demand to name two members of Commerzbank's supervisory board, and UniCredit will propose two independent members instead. Orcel wrote that the commitments "set the basis for the disposal of the government's stake". Klingbeil's statement, though, makes no promise of a sale.

Our note of 18 November said the state's stake and a few other holders could block a domination agreement, which only more buying by UniCredit could break; Berlin's support means the block may now fall without it. Such an agreement lets a parent give binding orders to a listed subsidiary, and it needs 75% of the capital present at a meeting. In August Bettina Orlopp, Commerzbank's chief executive, said structural changes of this kind are "key for the realization of major parts of synergies". Until now the state could block such a step with less than 4% of other shares, if no other holder at the meeting voted for it. If the state now votes with UniCredit, or sells its stake to it, opponents would need more than 21% of all shares, more than half of what everyone else owns.

For the other holders, the terms of the next step now matter more than the fight over control. A merger with HVB, which dpa says is expected, would put a value on each bank and set the ratio at which shares are swapped. A domination agreement would owe the remaining holders fair compensation and a guaranteed dividend. The bank is to stay listed, so a squeeze-out of the last holders is not part of the plan Berlin has backed. Orcel expects savings in the billions from a merger, which would benefit every holder if shared. How much of that gain reaches holders other than UniCredit depends on those terms.

The other reading is that the other holders still have two allies, Commerzbank's own board and the law. According to dpa, the board will protect the interests of all stakeholders, and in August Orlopp promised to "protect the rights of our minority shareholders". The law demands fair compensation in a domination agreement, and holders can go to court for more. What tips the balance for us is the board. At the meeting UniCredit plans for Q1 2027, dpa reports, all ten shareholder seats on the supervisory board are to be re-elected, which UniCredit's votes can decide. Finews reports that the management board under Orlopp is expected to be replaced too. The law is a real protection, but on our reading it sets a floor, a value worked out by experts, and does not make anyone bargain for the other holders.

Sources we read for this take

Reported: Reuters (19 Nov 2026), on Orcel's letter of 18 Nov 2026 and Klingbeil's statement; dpa via Handelsblatt and ad-hoc-news (19 Nov 2026), with Commerzbank's statement; EUobserver (16 Nov 2026); finews (16 Nov 2026)

Company: Commerzbank, UniCredit position page (read 19 Nov 2026)

Regulator: European Commission, Executive Vice-President Ribera's remarks (16 Nov 2026)

Calls: Commerzbank Q2 2026 call (6 Aug 2026)

Law: Baker McKenzie Global Public M&A Guide, Germany (domination agreement and squeeze-out thresholds)

Track record: vote thresholds, from our take of 18 Nov 2026

Our earlier take: Short sellers, frigates and perfume (18 Nov 2026)


IGD (IGD Italy): Carmila's terms are generous on income, with a risk for holders left behind

● POSITIVE

Carmila, which is taking over IGD's controlling stake, paid a dividend of €1.36 a share for 2025. At 0.31 Carmila shares per IGD share that is about €0.42, against the €0.15 IGD paid. Holders who do not swap could be left in a Carmila-controlled company with no date for a merger, with a legal exit if Carmila passes 90%.

Market cap €497m  ·  EV €1.3bn  ·  EV/EBITDA forward 13.3x  ·  Consensus upside 10.2%

On income, Carmila's terms are generous to IGD's minority shareholders, but those who do not swap could be left in a company Carmila controls, waiting for a merger. IGD is listed in Milan and owns shopping centres in Italy and Romania. Carmila, a Paris-listed owner of shopping centres anchored by food retailers, is taking over the 40.9% stake of Coop Alleanza 3.0, the cooperative that controls IGD. Coop Alleanza will receive 0.31 new Carmila share for each IGD share, and Carmila must then offer the same terms to every other IGD shareholder.

Before the deal, announced on 16 November, IGD was a listed landlord, controlled by Coop Alleanza, paying down debt. It had raised its 2026 guidance for funds from operations (FFO), the recurring cash profit of a property company, twice since February. Carmila paid a dividend of €1.36 per share in 2026 for the year 2025. At the exchange ratio that is about €0.42 for each IGD share, close to three times the €0.15 per share that IGD paid for the same year, both before tax. The offer is in shares, so the value of what holders receive will move with the value of Carmila's shares until the offer closes. Carmila says the ratio will be adjusted for any dividend either company pays before then, so neither side can tilt the terms that way.

Carmila's plan targets a payout of 75% of recurring earnings per share. IGD's €0.15 was only about two fifths of its 2025 FFO per share of about €0.37, and our take of 17 November argued that it had room to rise. Even IGD's whole 2025 FFO per share falls short of the €0.42 that Carmila's dividend for the same year gives. On this year's guidance of at least €47m, about €0.43 a share, a full payout would only just match that 2025 figure. Carmila's plan has its dividend rising every year from 2026.

Those dividend plans assume Carmila acquires all of IGD, delists it and merges it. The other reading is that IGD's lower payout leaves it more margin if rents or property values fall. Carmila expects the combined group's net debt to be 7.7 times EBITDA, its operating profit before depreciation, close to its own ceiling of 8 times. That estimate includes synergies and €20m of share buybacks. IGD's own net debt was 8.0 times EBITDA at the end of September. A holder who swaps therefore moves into a group with no more debt, measured against its earnings, than IGD has today, but with little room under Carmila's limit. Carmila's earnings growth target also assumes that its average cost of debt rises by about 0.3 points a year to 2031, which takes more of the earnings the 75% payout comes from. What tips the balance is the cushion: Carmila would have to cut its dividend by almost two thirds before the income per IGD share under the offer was lower than IGD's own €0.15.

Control by Carmila looks likely, but full ownership is less sure. Filings published by IGD on 18 November show that Unicoop Etruria, with about 10% of IGD, has committed to tender all its shares, subject to approval by its supervisory board on 27 November and consent from a lender. With Coop Alleanza's stake that would give Carmila about 50.9%. Carmila expects the offer to close before May 2027. The offer aims to delist IGD, and if that fails Carmila has committed to make its best efforts to merge IGD into itself.

If the offer takes Carmila above 90%, it must take the remaining shares from anyone who asks, unless within 90 days it puts enough shares back on the market for normal trading. The terms would be tied to the offer or set by Consob, the market regulator, depending on how the stake was built. Below that level, holders who stay would own part of a listed company that Carmila controls, whose dividend Carmila would decide, with no date for a merger. The more holders swap, the fewer shareholders and the thinner the trading left for those who do not. Carmila expects earnings per share to rise by about 1.5% and net asset value per share by about 2% on full ownership, a reason for it to see a merger through.

Sources we read for this take

Company: Release on the Carmila combination (16 Nov 2026); release and essential information on the shareholder agreements under art. 122 TUF, Coop Alleanza and Unicoop Etruria (18 Nov 2026); results as of 30 Sep 2026 (12 Nov 2026); 2025 results (26 Feb 2026)

Bidder: Carmila 2027-2031 strategic plan, regulated release on Euronext Paris (18 Nov 2026)

Law: Italian Consolidated Law on Finance (D.Lgs. 58/1998) art. 108

Track record: FFO guidance and dividend room, from our take of 17 Nov 2026

Our earlier take: Turbines, tickets and tungsten (17 Nov 2026)


PORR (POS Austria): A strong summer puts the margin target within reach, if the fourth quarter repeats last year's

● POSITIVE

The 2026 targets require EBIT of about €83m to €94m from October to December, 5.2% to 5.4% of revenue, against about €89m and 5.3% in 2025. Net debt without September's hybrid bond is closing in on last year's level, with the gap down from €159m at the end of June to €55m.

Market cap €1.3bn  ·  EV €773m  ·  EV/EBITDA forward 1.7x  ·  Consensus upside 30.3%

PORR should reach its 2026 margin target, because it needs a fourth quarter only about as strong as last year's, and the summer catch-up gives it a good run-up. PORR, the Austrian construction group, builds roads, railways, tunnels and buildings, mainly in Austria, Germany, Poland, the Czech Republic, Slovakia and Romania. Its output, which also counts PORR's share of joint ventures, rose 11.5% in the third quarter as the group caught up after a long winter. Free cash flow in the quarter reached €116m, against almost nothing a year earlier. PORR confirmed its targets for this year of 2% to 4% revenue growth and an EBIT margin of 3.2% to 3.3%.

Builders earn much of their profit at the end of the year, so the targets have to be read against the fourth quarter. Revenue would already sit inside the range if the last quarter only matched a year ago, and the top end needs growth of less than 4%. The margin is harder, because PORR needs fourth-quarter EBIT of roughly €83m to €94m, a margin of about 5.2% to 5.4%. Last year's fourth quarter made about €89m, or 5.3%, in what the company called the best year in its history.

Third-quarter revenue rose 13.5%, taking nine-month revenue up 4.1% to €4.8bn. Profit grew more slowly, so the quarter itself gives little sign of a rising margin. EBIT rose 10.9% to €65.9m and the quarterly margin slipped to 3.5% from 3.6%. Income from joint ventures and associates more than halved in the quarter. The nine-month margin rose to 2.5% from 2.3%, but partly on one-offs, mainly higher insurance payments and a property sale by a joint venture, against a write-down linked to the planned disposal of a subsidiary.

The other reading is that the slipping third-quarter margin and the one-offs point to a weaker year-end than last year's. What tips the balance is that last year's fourth quarter already made 5.3%, inside the range the target needs. PORR's record on its own targets also helps: a year ago it expected 2025 EBIT of €180m to €190m, and it delivered €197m. Our take of 8 October said the nine-month figures would show whether the delayed building season had been caught up. For the group it largely has, as building construction went from a 2.6% fall in output in the first half to growth of 1.6% over nine months. Germany is the exception. Its output is down 8.0%, partly because a large project was finished, and the company says the third quarter was not yet enough to make up for the late start there.

Germany is also where PORR's order book now grows fastest, after a 50.2% jump in orders. The new work includes barracks for the German army, a chip plant for X-FAB, a chipmaker, and a meat plant for EDEKA, a supermarket group, and the German backlog is up 27.2%. Its larger Austrian rival Strabag saw its third-quarter output growth led by Germany, where energy, rail and industrial building are expanding. Strabag has also raised its 2026 margin target twice in three months, to 6% to 6.5%. Strabag already gets its growth from Germany, and PORR's German orders should follow from 2027, too late to help this year's target.

In Poland, the Czech Republic, Slovakia and Romania output grew strongly, but orders fell and their combined backlog is down about 9%. Romanian contract awards stalled until a government was formed in mid-October, and PORR now expects an expressway contract of around €550m there, while Polish tenders worth up to €4.5bn are in the final offer phase. The group backlog still rose 4.4% to €10.0bn, which the company says secures about a year and a half of work.

Reported net debt fell sharply, but the whole fall comes from September's bond, and the gap underneath is closing quickly. Net debt dropped to €215m, helped by the €150m hybrid convertible bond, which counts as equity. Without it, net debt was €362m, about €55m more than a year earlier, down from a gap of €159m at the end of June. After the third quarter's cash inflow, PORR expects clearly positive operating cash flow for the year.

Sources we read for this take

Company: Q3 2026 release and interim report (19 Nov 2026); preliminary FY 2025 release (4 Mar 2026); Q3 2025 release (20 Nov 2025)

Peers cross-read: Strabag Q3 2026 trading update and margin upgrade, from our take of 12 Nov 2026

Track record: 2025 EBIT guidance against delivery, from our take of 20 Nov 2025 and the FY 2025 release

Our earlier take: Construction, eyewear and beer (8 Oct 2026)


Flughafen Wien (FLU Austria): Nine months already meet the profit guidance, so the targets look far too low

● POSITIVE

Nine-month EBITDA rose 4.2% to €392.8m and net profit 2.9% to €221.9m, against full-year guidance of about €425m and €220m. Vienna passengers fell 4.5% to September and 7.7% in October, while Malta's EBITDA grew 17.9%.

Market cap €4.2bn  ·  EV €4.3bn  ·  EV/EBITDA forward 9.7x  ·  Consensus upside 12.7%

Flughafen Wien has already earned the profit it guided for the whole year, so it should beat its unchanged targets comfortably, even with fewer passengers in Vienna. The company runs Vienna airport and holds stakes in the airports of Malta and Kosice. After nine months, net profit before minorities was €221.9m, against guidance of about €220m for the year. EBITDA was €392.8m, against about €425m.

Taken literally, the targets leave the fourth quarter with EBITDA of about €32m and a small net loss, which looks very cautious. The same reading proved too low a year ago: the 2025 guidance of about €440m left about €63m for the fourth quarter, which then made about €91m of EBITDA before the €55.9m write-off of the third runway project.

The profit growth comes from Malta and from lower costs, while traffic in Vienna is falling. Malta's EBITDA rose 17.9% to €89.6m on 14.5% more passengers. Group personnel costs fell to €303.9m from €307.8m, and other operating costs to €127.9m from €134.9m. In Vienna, passenger numbers fell 4.5% to 23.5m in the first nine months and 7.7% in October. The company puts that down to low-cost airlines cutting capacity and the conflict in the Middle East. Group revenue was flat at €846.6m, with lower airport charges in force since January.

Our take of 18 November 2025 said it was hard to see EBITDA growing in 2026 unless passenger numbers picked up clearly. Traffic did not pick up, and nine-month EBITDA still rose 4.2% on Malta and lower costs. For the full year the comparison is harder, because 2025 EBITDA before the write-off was about €468m, well above this year's guidance. Matching it needs about €75m in the fourth quarter, against about €91m a year earlier before the write-off.

Vienna is the weak spot, with traffic falling faster than in the first half, so the positive reading here rests on profit against the guidance, not on traffic. The company keeps pressing for the air transport levy to be abolished or cut. The next step for its income from shops and restaurants is the southern terminal extension, due in April 2027. It adds 70,000 m² with new shops, restaurants, lounges and a central security check.

Sources we read for this take

Company: Q1-3 2026 release (19 Nov 2026); FY 2025 results release (2 Mar 2026)

Track record: 2025 guidance against delivery, from our take of 18 Nov 2025

Our earlier take: Energy solutions, construction and flying trains (27 Aug 2026)


Ferrari Group (FERGR Netherlands): After a fast third quarter, the unchanged range for the year looks too low

● POSITIVE

Nine-month revenue is up 8.0% at constant currency against a full-year range of 4-6%. The €38m Americas buyout and the €20m special dividend come to €58m, about three-quarters of the €78.0m net cash at the end of June.

Market cap €740m  ·  EV €676m  ·  P/E forward 12.8x  ·  Consensus upside 35.6%

Ferrari Group has kept its revenue forecast for the year unchanged, but after a fast third quarter the range looks too low. The London-based company, listed in Amsterdam, provides shipping and logistics for luxury goods, including watches, and also transports gold, in more than 60 countries. Its revenue rose 8.0% at constant currency over the first nine months, while the range for the full year is still growth of 4-6%.

On our calculations, the nine months come to about €284.5m at 2025 exchange rates. The top of the range then needs about €96.5m in the fourth quarter, level with the €96.0m of a year ago, while the bottom allows about €89.3m, a fall of about 7%. The company itself expects momentum "to continue into the fourth quarter, in line with historical seasonal trends", which would take the year above the range.

The third quarter was the fastest so far, with revenue up 13.4% to €95.0m, or 11.7% at constant currency, after 6.2% in the first half. North America and Brazil grew 26.9% at constant currency. That was helped by the local agent in Brazil bought in the first quarter, so not all of it comes from the existing business. Domestic Services rose 25.5% at constant currency on strong demand for gold shipments, which the release says was "supported by favourable gold prices", and on better operations in Germany. That part of the growth depends on gold staying high. Asia grew 9.1% at constant currency, enough to bring its nine months to a decline of 0.5%.

On margins the release only repeats the target of an adjusted EBITDA margin "broadly stable at or around FY 2025's 26%". The first half was 25.5%, so the second half has to run slightly above 26%, and a strong fourth quarter is the likeliest way to get there.

Our take of 8 September expected larger payouts if no sizeable deal came along, and on 17 September we noted that the board could consider a special dividend. The board has now done a deal and declared a special dividend anyway, which says it sees more cash than the business needs. Ferrari Group is paying €38m for the remaining 50% of its subsidiaries in the United States, Canada and Brazil, its fastest-growing region, and a special dividend of €20m. Together that is €58m, about three-quarters of the €78.0m of net cash at the end of June, before the second half's cash flow. On the June figures, the payments leave about €20m of net cash before anything the second half adds, and the first half alone brought €30.2m of operating cash. The group therefore stays free of net debt, but these payments use most of the money it had for a larger deal. The release gives no profit for the Americas companies, but the price does not look cheap. All minority shareholders together took €2.7m of the group's 2025 profit. Even if the Americas partners had taken all of it, €38m is at least about 14 times their share.

Sources we read for this take

Company: Q3 2026 trading update (19 Nov 2026); Americas acquisition and special dividend release (18 Nov 2026); FY 2025 results (9 Apr 2026)

Track record: capital allocation: larger distributions expected if no sizeable deal appeared, from our takes of 8 Sep and 17 Sep 2026

Our earlier take: Electrification, trucks and strong catalysts (17 Sep 2026)


Interparfums (ITP France): Growth returns in 2027 at a roughly steady underlying margin, so it rides on launches

● POSITIVE

2027 sales are guided to about €960m at constant exchange rates with an operating margin of about 17%, while marketing rises to 24-25% of sales. Without the €10m tariff refund in 2026, and on the company's rounded margins, underlying operating profit would grow roughly in line with sales.

Market cap €3.2bn  ·  EV €3.2bn  ·  P/E forward 25.1x  ·  Consensus upside -1.6%

Interparfums expects sales to grow again in 2027 at a roughly steady underlying margin, even with more marketing, so the year depends on its new perfumes selling well. The Paris company makes and sells fragrances under licence for brands such as Coach, Montblanc, Jimmy Choo and Lacoste. After 2026, which it calls "a year of consolidation", it now projects sales of about €960m at constant exchange rates for 2027. That is about 9% above its raised 2026 target of €880m and about 7% above the €899m of 2025.

Sales started to recover in the summer after falling about 7% in the first half of 2026. They rose 4.8% in the third quarter on Coach and Montblanc, and the company says momentum improved "especially in recent weeks". That allowed it to lift the 2026 target from €870m to about €880m. With nine-month sales of €679.8m, the new target needs about €200m in the fourth quarter, roughly level with the €199m we estimated for the same quarter of 2025 in our take of 22 October. After a third quarter up 4.8%, a flat fourth quarter still looks like a cautious target.

Interparfums is counting on what it calls an intense launch plan to deliver 2027. The first half brings new franchises for Lacoste, Coach and Montblanc. The second half brings the first Longchamp fragrances since that licence was signed in July 2025, and Off-White and Annick Goutal add sales as new brands. To support all this, marketing and advertising will rise to 24-25% of sales, about €230-240m on €960m. That is 3 to 4 points of sales above the 21% of 2024, the last full year for which we have the figure; the company has not given a full-year figure for 2026.

The operating margin is projected at about 17%, down from about 18% in 2026, yet that comparison overstates the drop. The 2026 figure includes a one-off €10m refund of US tariffs. Without it, our calculation gives about €148m of operating profit for 2026, also close to 17% of €880m. A 17% margin on €960m is about €163m, so underlying operating profit would grow roughly in line with sales. Both margins are rounded in the release, so half a point either way moves that growth rate by several points. The 2027 sales figure is also at constant exchange rates, while 2026 is reported.

With marketing at 24-25% of sales, a 17% margin leaves little room if the launches start slowly. Guiding marketing as a share of sales gives some protection, since weaker sales should pull spending down with them. The first half of 2026 shows the limit of that protection: marketing rose to 20% of sales from 18.1% while sales fell 7.3%, because the company kept spending to support its lines and prepare the 2027 launches. The same half brought a higher gross margin, 67.3% against 65.5%, which the company put down to its higher-margin US subsidiary. That half also carried the US tariff refund, and the figures we have do not show where it was booked, so we do not count on that gain to pay for the extra marketing.

Interparfums Inc., the US company that owns most of the shares, guided a day earlier to diluted earnings per share up 3% to about $5.00 for 2027. Its 2026 figure includes a $0.35 benefit from the tariff refund that 2027 does not repeat, and without it growth would be about 11%. It also flags "continuing challenges in the Middle East and Eastern Europe" for the European business. Europe was the open point in our take of 10 September, which said the 2027 launches had to restart growth at Lacoste and in Europe to justify the 2026 marketing bill. Lacoste has made a start, up 5% in the third quarter after a 21% fall in the first half, and it gets a new franchise in the first half of 2027. The release says nothing about Europe, Lanvin or Rochas, so the recovery still rests mainly on Coach and Montblanc.

Sources we read for this take

Company: 2027 outlook release (19 Nov 2026)

Filing: Interparfums Inc. Form 8-K, 2027 guidance (18 Nov 2026)

History: margin, gross margin and marketing share, from our takes of 26 Feb 2025, 9 Sep 2025, 10 Sep 2026

Our earlier take: Trading, electrification and a lot of results (22 Oct 2026)


Sage (SGE UK): A 10% start to the new year rests on existing customers paying more

● POSITIVE

Net revenue retention rose to 103% from 101%, while ARR from new customers grew to £205m from £200m. FY27 brings a restructuring charge of around £100m outside underlying profit, and leverage sits at 2.0x, the top of Sage's 1x to 2x range.

Market cap £10.2bn  ·  EV £11.7bn  ·  P/E forward 19.5x  ·  Consensus upside 7.8%

Sage starts its new financial year expecting slightly faster growth than a year ago, and the extra comes mainly from existing customers paying more, while the amount of new business won each year barely grew. The UK company sells finance, HR and payroll software to small and mid-sized businesses and their accountants, mostly by subscription. It expects organic total revenue growth "in the region of 10%" in the year to September 2027. A year ago its starting guidance was "9% or above", raised to "above 9%" in May, and the year closed at 10%.

That is a good set of numbers, with higher guidance, better retention and a wider margin. Sage describes its growth in annual recurring revenue (ARR) as "balanced between new and existing customers". Organic ARR rose by £280m to £2,866m, of which £205m came from new customers and about £75m net from existing ones, so new customers still bring most of the growth. What changed from last year is the existing side. Net revenue retention, which shows how much more existing customers pay each year after some of them leave, rose to 103% from 101%. Sage puts that down to "higher sales to existing customers, including the growing adoption of AI-powered features and targeted price rises". New customers added only about 2.5% more ARR than the £200m of a year earlier.

Each point of retention is worth about £26m of ARR, so the two-point rise added about a quarter as much as a full year of new-customer wins. Part of it comes from price rises, so retention will stay at this level only if the AI features keep selling.

Using July's nine-month update, we estimate that organic revenue growth slowed a little late in the year, from about 10.8% in the third quarter to about 10.0% in the fourth. Sage Intacct, its cloud accounting product for mid-sized companies, grew 24% in the US for the year to £559m. It grew 26% in the first half, so the second half ran at roughly 23%. Intacct is about half of US revenue, so its pace largely sets the region's. Our May take said Intacct was doing most of the work in the US, and it still is, at a slightly lower rate.

Profits grew faster than revenue, with underlying operating profit up 13% to £681m and the margin up 0.6 points to 24.5%. The next step has a cost that those underlying figures will not show. Sage expects a restructuring charge of around £100m in FY27 from reducing management layers and consolidating technology in key hubs, with the savings reinvested. The charge sits outside underlying profit. If most of it is paid in cash, it equals about 17% of FY26 free cash flow of £575m.

That free cash flow was already spent, because buybacks of £604m and dividends of £209m took out more than Sage generated. Net debt rose to £1,582m and leverage reached 2.0 times underlying EBITDA, the top of the 1 to 2 times range Sage aims for, although it keeps the "flexibility to move outside this range". A year ago Sage announced a £300m buyback with its results, and today's release announces none. With the restructuring charge and the balance sheet where it is, buybacks this year are likely to be smaller than the roughly £600m a year of FY25 and FY26.

Sources we read for this take

Company: FY26 results release (19 Nov 2026); Q3 trading update (29 Jul 2026); H1 FY26 results (21 May 2026); FY25 results and buyback release (19 Nov 2025)

Track record: FY26 revenue guidance and delivery, from the company's releases of 19 Nov 2025, 21 May 2026 and 29 Jul 2026

Our earlier take: Semis, luxury and ugly cars (26 May 2026)


Rubis (RUI France): The general partners take less and holders get cash, which should carry the vote

● POSITIVE

The general partners would now get about 11.4m new shares, about 11% of the capital before the issue, against 12.7m and 12.3% in October, and existing shares get €1.50 each in cash. Three holders with about 20.7% of the capital say they intend to vote for it on 9 Dec.

Market cap €3.8bn  ·  EV €5.7bn  ·  EV/EBITDA forward 6.8x  ·  Consensus upside 14.4%

Rubis has given some of its largest shareholders close to what they asked for, and that should be enough to end its old partnership structure at the vote on 9 December. The French company sells fuel, liquefied gas and bitumen in Africa, the Caribbean and Europe, and also builds solar parks. It is run as a partnership limited by shares. In this French structure, the general partners control management with just over 2% of the capital. Rubis now wants to become an ordinary company with a management board, and the general partners are to be paid in new shares for giving up their rights.

The first offer, made in October, gave the general partners 12.7m new shares, 12.3% of the capital before the issue and the top of the range set by Ledouble, the independent expert appointed by the supervisory board. The change needs two-thirds of the votes. Boursier reported on 10 November that Patrick Molis, whose Compagnie nationale de navigation holds about 9%, wanted the payment capped at 10% of the capital. It also reported, citing Wansquare, that Vincent Bolloré's Plantations des terres rouges, with about 6%, planned to vote against unless it came down. Neither Rubis nor the two holders have confirmed those reported positions. When the dilution came up on the 3 November call, management pointed to the expert's valuation.

The revised terms, backed by the supervisory board on 18 November, move a long way towards those reported demands. The general partners would now receive about 11.4m new shares, the bottom of the expert's range: about 11% of the capital before the issue, or 9.9% after it. Every existing share would also get €1.50 in cash, about €155m in total. The new shares are left out of that payment, which keeps about €17m away from the general partners on top of 1.34m fewer shares. Molis's company and Plantations des terres rouges, together with Groupe Industriel Marcel Dassault, have now told Rubis they intend to vote for the package, and the three hold about 20.7% between them. The cash, the conversion and the new supervisory board are tied together, so holders cannot take the payout and reject the rest. The AMF, the French market regulator, still has to confirm that no buyout offer is required.

Paying out €155m in cash adds the same amount to net debt. Corporate net debt, which leaves out the project debt of the solar business, stood at €885m in June, or 1.3 times EBITDA on Rubis's own measure. That is lower than the 1.4 times of June 2025, but up from 0.9 times at the end of 2025, because the annual dividend is paid in the first half. On the June figures, the special payout alone would lift the ratio to about 1.5 times. When we looked at Rubis in September 2025, solar spending was running ahead of what the business could fund on its own after dividends. Investment has come down since, to €137m in the first half from €164m a year earlier. Operating cash flow, though, also had to absorb more working capital as oil prices rose. On top of that came a €64m fine in Corsica from the French competition authority, which Rubis is contesting. In October Rubis said the new structure would give it more financial room for acquisitions, and this payout spends part of that room before any deal.

Sources we read for this take

Company: Revised conversion terms release (18 Nov 2026); conversion proposal (19 Oct 2026); H1 2026 results (8 Sep 2026); Q3 2026 trading update (3 Nov 2026)

Calls: Rubis Q3 2026 call (3 Nov 2026)

Reported: Boursier (10 Nov 2026)

Track record: corporate net debt and capex, from our take of 11 Sep 2025

Our earlier take: Clothes, gambling and metal jackets (11 Sep 2025)


Novartis (NOVN Switzerland): The new five-year target suggests a weak 2031, when Kisqali and Kesimpta lose patents

● NEGATIVE

Sales are now guided to grow 5% a year at constant currencies from 2026 to 2031, against 5-6% a year for 2025-2030 before. Peak sales forecasts rise for Kesimpta, Scemblix and Leqvio, and the core margin is still to return to 40%+ by 2029.

Market cap CHF 260.3bn  ·  EV CHF 293.4bn  ·  P/E forward 15.3x  ·  Consensus upside 1.8%

Novartis now expects more from several of its newer drugs, but its new five-year sales target suggests a weak 2031, the year Kisqali and Kesimpta start to lose patent protection. Ahead of its investor event in London today, the Swiss drugmaker said it expects sales to grow 5% a year on average from 2026 to 2031, at constant currencies. A year ago it promised 5% to 6% a year from 2025 to 2030.

Novartis is in the middle of what its chief executive calls "the largest loss-of-exclusivity impact in our history". Since the third quarter of 2025 its heart failure drug Entresto has faced cheaper generic copies in the US, and older brands such as Promacta and Tasigna are shrinking fast. Sales were flat at constant currencies over the first nine months of this year, and for the full year the company expects low single-digit growth.

Moving the target window on by a year should have made 5% easier to reach, because the flat year 2026 becomes the starting point. Yet the new figure sits at the bottom of the old range. Suppose 2026 ends with growth of about 1.5%, which already needs a strong fourth quarter after flat sales over nine months. Then the old range needed roughly 6% to 7% a year from 2027 to 2030. If Novartis still sees that path, and taking the 5% at face value, the last year comes out somewhere between growth of 1.5% and a fall of about 3%, and lower still if 2026 ends weaker. That would fit our take of 27 August, which flagged 2031 as the year Kisqali and Kesimpta, then around 26% of sales, face patent expiries.

The other reading is that the path to 2030 itself has come down. The pipeline has had a difficult year: the del-desiran readout in muscular dystrophy disappointed, and Novartis took a USD 1.9 billion impairment on that drug in the third quarter. The release does not split the five years, so it does not settle the question. What tips the balance towards a weak 2031 is that the drugs selling before then now have higher peak sales forecasts. Kesimpta, for multiple sclerosis, rises to USD 8 billion from USD 6 billion. Scemblix, for leukaemia, and Leqvio, which lowers cholesterol, both rise to USD 5 billion from USD 4 billion. On our calculations the Kesimpta figure is within reach: it sold USD 1,484 million in the third quarter, about USD 5.9 billion a year at that pace, and still grew 22% at constant currencies.

Novartis still says its core operating margin is "on track to return to 40%+ by 2029", the date it gave a year ago. Back then it said buying Avidity Biosciences would cost 1 to 2 points of margin for a while. Over the first nine months of this year the margin was 40.1%, already 1.1 points lower than a year earlier and only just above the 40% line. The 2027 guidance will show whether it falls below that line before the promised return in 2029.

AstraZeneca shows what steadier growth looks like over the same period: its product sales rose 5% at constant exchange rates in the first nine months, and it says it is on track for its 2030 goal. Novartis is counting on more than 35 trial readouts through 2031 to keep growing after 2030. Our take of 8 September, written after the heart drug pelacarsen failed a large trial, said cardiovascular development "now depends more heavily on Leqvio and abelacimab", a blood thinner for patients with atrial fibrillation. Both are highlighted today, and their outcome studies report in 2027.

The full-year results in early February will give the first answer. Guidance of 6% or more for 2027, or high single-digit growth, would put Novartis back on the path the old range needed, and make a weak 2031 the reason for the lower target. Mid single-digit growth would leave the question open. Low single digits would suggest the whole path has come down.

Sources we read for this take

Company: Release on mid-term guidance for Meet Novartis Management (19 Nov 2026); Release on mid-term guidance (20 Nov 2025); Q3 2026 release (27 Oct 2026)

Peers cross-read: AstraZeneca 9M and Q3 2026 results (30 Oct 2026)

Our earlier take: Streaming, DIY and cheap razors (8 Sep 2026)